Page 5 - Advanced Accelerator Applications News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Novartis Mulls Divesting Some Assets Of Radiopharma Unit In Strategic Shift - Novartis (NYSE:NVS)

Swiss pharmaceutical giant Novartis AG (NYSE: NVS) is reportedly contemplating selling sections of radiopharmaceuticals company Advanced Accelerator Applications to align with the company's strategy and the broader industry trend to shed low-growth segments.

European organization for nuclear researchChinook therapeutics incAdvanced accelerator applicationsAccelerator applicationsChief executive officerVas narasimhanEuropean organizationNuclear research

Roundtable: Understanding challenges in nuclear medicine delivery

Roundtable: Understanding challenges in nuclear medicine delivery
hsj.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hsj.co.uk Daily Mail and Mail on Sunday newspapers.

United kingdomNovartis companyOperational delivery networksAdvanced accelerator applicationsWilmington healthcareAdvanced accelerate applicationsAdvanced accelerator applications led

Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United statesNew jerseyBaja californiaMarlena abdinoorJeff legosParag mahantiRichard jarvisSatoshi sugimotoIsabella zinckSamir shahSloan simpsonJulie masowNicole zinsli sommMichael meoGlobal head of oncology development at novartisExchange commission

Nusano Appoints Industry Expert Alexandre Gibim as Chief Operations Officer

Nusano Appoints Industry Expert Alexandre Gibim as Chief Operations Officer
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

West valley cityUnited statesJoyce allaireChris loweAlexandre gibimHoward lewinScott larriveeNusano incProduct developmentLifesci advisorsAppoints industry expert alexandre gibimChief operationsChief operations officerNorth americaAdvanced accelerator applicationsChief product development officer

Peptide Receptor Radionuclide Therapy (PRRT) Market Report: Unveiling a 7 2% CAGR Ascent Toward US$

During the forecast period, the peptide receptor radionuclide therapy (prrt) market is expected to grow at a strong CAGR of 7.2%. The market is currently worth US$ 552.08 million in 2022 and is expected to grow by US$ 1,106.50 million by 2032.This Peptide Receptor Radionuclide Therapy market study offers a comprehen.

United statesNew yorkGreater new york chamberDrug administrationMarket insights incEuropean commissionConsumer technologyPeptide receptor radionuclide therapyPeptide receptor radionuclide therapy prrtReceptor radionuclide therapyComprehensive informationAdvanced accelerator applicationsAccelerator applicationsFuture market insightsMarket insightsStevie award